Blue Wolf Capital to Acquire OSD CDMO Sites from Recipharm

Seven sites across Sweden, France and Spain to form new CDMO platform

NEW YORK--(BUSINESS WIRE)--Blue Wolf Capital Partners LLC (“Blue Wolf”), a middle market private equity firm specializing in the healthcare and industrial sectors, announced today that it has committed, subject to regulatory clearances, to acquire seven manufacturing and development facilities: Solna, Stängnäs, Höganäs, Karlskoga and Uppsala OTC Development in Sweden, Pessac in France, and Parets in Spain, from Recipharm, a contract development and manufacturing organization (“CDMO”) headquartered in Stockholm.

The seven facilities have been a part of Recipharm for over a decade and have focused on the manufacturing and development of oral solid, semi-solid and liquid dosage form pharmaceutical products. The facilities serve over 120 customers around the world and have a strong track record of quality and regulatory compliance. Together these sites are to form a new independent CDMO platform with continued focus on pharmaceutical manufacturing operating under a new corporate name to be announced after the transaction closes.

“Blue Wolf is excited for the opportunity to build a new CDMO platform with these seven European assets serving as a cornerstone,” said Shashank Patel, Principal at Blue Wolf. “Partnering with the leadership and teams at these seven facilities, we look forward to continuing to deliver world-class manufacturing capabilities and development services to our partners in order to provide the highest quality pharmaceuticals to patients around the world.”

Greg Behar, CEO, Recipharm said: “We are delighted that Blue Wolf has committed to acquire seven of our OSD sites, marking a significant step for both organizations. I am confident that Blue Wolf will continue to elevate service excellence and bolster the organization for the benefit of customers and patients. By consolidating our site network, we are sharpening our focus on New Chemical Entities (NCEs), medium to high potency drugs, and on-patent medications within the oral solid dosage sector. This strategic divestment aligns with our overarching vision to emerge as the premier choice CDMO for both our customers and patients. I extend my best wishes to all our colleagues embarking on this new journey at those seven sites."

Terms of the agreement were not disclosed. The transaction is expected to close in Q4 2024, subject to customary regulatory approvals.

About Blue Wolf Capital Partners

Blue Wolf Capital Partners LLC is a private equity firm that focuses on value investments in middle market companies in the healthcare and industrial sectors. The firm’s integrated team of investment professionals and veteran operating executives work collaboratively to generate returns by driving transformational change using operational and strategic experience. Blue Wolf seeks to invest in businesses that have catalysts for value creation that involve organizational transformation, complex union or human capital issues, significant government presence, or the opportunity to use ESG-informed strategies. For additional information, please visit www.bluewolfcapital.com.

About Recipharm

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing over 7,400 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden.

For more information on Recipharm and our services, please visit www.recipharm.com